Zobrazeno 1 - 10
of 27
pro vyhledávání: '"J A, Maroun"'
Publikováno v:
British Journal of Cancer
Thymidylate synthase (TS) is the enzyme that catalyses the last step in de novo thymidylate synthesis. It is of interest clinically because it is an effective target for drugs such as 5-fluorouracil, often used in combination therapy. Despite a numbe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e89bee49ecd7a29f2885ccbcc17f0f3b
http://europepmc.org/articles/PMC2360461
http://europepmc.org/articles/PMC2360461
Publikováno v:
Journal of forensic sciences. 46(5)
A preliminary study was conducted to assess the capability of a new alcohol-based tissue fixative, GenoFix, to preserve DNA from biopsy tissues stored at room temperature and/or -20 degrees C in a freezer, for subsequent short tandem repeat (STR) DNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d9861f66d6ce27a1b246d3aad9fd634c
https://pubmed.ncbi.nlm.nih.gov/12570249
https://pubmed.ncbi.nlm.nih.gov/12570249
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
Autor:
L B, Saltz, J V, Cox, C, Blanke, L S, Rosen, L, Fehrenbacher, M J, Moore, J A, Maroun, S P, Ackland, P K, Locker, N, Pirotta, G L, Elfring, L L, Miller
Publikováno v:
The New England journal of medicine. 343(13)
The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4df76fc1bacc44e9efd5d30b2facb1a8
https://pubmed.ncbi.nlm.nih.gov/11450667
https://pubmed.ncbi.nlm.nih.gov/11450667
Publikováno v:
Investigational new drugs. 16(1)
Didemnin B (NSC-325319), a new depsipeptide isolated from a Caribbean tunicate, has been evaluated in a clinical phase I study. The drug was administered in a schedule of a 4 weekly intravenous injection in a six-weeks cycle. Fifty-three patients rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::42f2b7a5ce02f7c6c3aea615381d695f
https://pubmed.ncbi.nlm.nih.gov/9740544
https://pubmed.ncbi.nlm.nih.gov/9740544
Autor:
W K, Evans, A, Radwi, E, Tomiak, D M, Logan, H, Martins, D J, Stewart, G, Goss, J A, Maroun, S, Dahrouge
Publikováno v:
American journal of clinical oncology. 18(2)
Elderly patients with small cell lung cancer (SCLC) and/or those with comorbid conditions are frequently not considered candidates for standard combination chemotherapy. An active, but less toxic regimen is needed for this group of patients.Forty-sev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::198765fb589e7b8a56b67cda354af8ce
https://pubmed.ncbi.nlm.nih.gov/7534977
https://pubmed.ncbi.nlm.nih.gov/7534977
Autor:
J. Zabransky, P. Douglas, M. Ruzic, G. Georget, S. Yunger, L. Blair, D. Milliken, J. A. Maroun, D. Shum, M. Byrne
Publikováno v:
Journal of Clinical Oncology. 28:e16533-e16533
e16533 Background: In Canada, IV cancer drugs are normally funded through the public health care system and administered in hospitals and cancer centers. Drugs not publicly funded are sometimes pai...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1d42ac210b3b7bbf6a34215a5ad3a02
https://doi.org/10.1200/jco.2010.28.15_suppl.e16533
https://doi.org/10.1200/jco.2010.28.15_suppl.e16533
Autor:
D J, Stewart, S E, Aitken, S, Verma, J A, Maroun, L, Robillard, M, Touchie, I A, Prosser, R, Earhart
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 3(5)
Twenty-eight patients were treated with oral menogaril daily x 14 every 4 weeks. Granulocytopenia was dose-limiting at 50-60 mg/m2 per day. Neutropenic fever occurred in one patient. Thrombocytopenia occurred in 3 of 6 patients treated with menogaril
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::74daf7ece41f2bcaa5e939e9e4eea0a2
https://pubmed.ncbi.nlm.nih.gov/1535508
https://pubmed.ncbi.nlm.nih.gov/1535508
Publikováno v:
Journal of Clinical Oncology. 27:e17502-e17502
e17502 Background: Capecitabine is an oral fluoropyrimidine used to treat patients with metastatic colorectal cancer (mCRC). Recent trials in 1st- and 2nd-line treatment have shown that capecitabine in combination with oxaliplatin (XELOX) is non-infe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a946ee1df9b63f4762312aebbb53ad0
https://doi.org/10.1200/jco.2009.27.15_suppl.e17502
https://doi.org/10.1200/jco.2009.27.15_suppl.e17502
Publikováno v:
Anticancer research. 11(1)
Two human small cell lung cancer (SCLC) cell lines were used to evaluate the in vitro response to lonidamine and cisplatin exposure. The two cell lines both showed growth inhibition when exposed to lonidamine alone at concentrations greater than 50 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6bcc92a32cb5babe3e154def0ef86cd8
https://pubmed.ncbi.nlm.nih.gov/1850216
https://pubmed.ncbi.nlm.nih.gov/1850216
Autor:
G P, Raaphorst, M M, Feeley, D P, Heller, C E, Danjoux, L, Martin, J A, Maroun, A J, De Sanctis
Publikováno v:
Anticancer research. 10(4)
Lonidamine combined with cisplatin treatment was tested in human glioma (U87MG) human squamous cell carcinoma (UMSCCl) and Chinese hamster (HA1) cells. The order of sensitivity to cisplatin was HA1 greater than U87MG greater than UMSCCl. Lonidamine c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e43238b472ef1b70087f87f3aafa827
https://pubmed.ncbi.nlm.nih.gov/2382989
https://pubmed.ncbi.nlm.nih.gov/2382989